- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04246047
Bewertung der Wirksamkeit und Sicherheit von Belantamab Mafodotin, Bortezomib und Dexamethason im Vergleich zu Daratumumab, Bortezomib und Dexamethason bei Teilnehmern mit rezidiviertem/refraktärem multiplem Myelom (DREAMM 7)
DREAMM 7: Eine multizentrische, offene, randomisierte Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit der Kombination von Belantamab Mafodotin, Bortezomib und Dexamethason (B-Vd) im Vergleich zur Kombination von Daratumumab, Bortezomib und Dexamethason (D-Vd ) bei Teilnehmern mit rezidiviertem/refraktärem Multiplem Myelom
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Erweiterter Zugriff
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- GSK Investigational Site
-
Liverpool, New South Wales, Australien, 2170
- GSK Investigational Site
-
Newcastle, New South Wales, Australien, 2298
- GSK Investigational Site
-
St Leonards, New South Wales, Australien, 2065
- GSK Investigational Site
-
Wollongong, New South Wales, Australien, 2500
- GSK Investigational Site
-
-
Queensland
-
Benowa, Queensland, Australien, 4217
- GSK Investigational Site
-
Herston, Queensland, Australien, 4029
- GSK Investigational Site
-
-
South Australia
-
Ashford, South Australia, Australien, 5037
- GSK Investigational Site
-
-
Victoria
-
Box Hill, Victoria, Australien, 3128
- GSK Investigational Site
-
Heidelberg, Victoria, Australien, 3084
- GSK Investigational Site
-
Melbourne, Victoria, Australien, 3004
- GSK Investigational Site
-
-
Western Australia
-
Murdoch, Western Australia, Australien, 6150
- GSK Investigational Site
-
Nedlands, Western Australia, Australien, 6009
- GSK Investigational Site
-
-
-
-
-
Roeselare, Belgien, 8800
- GSK Investigational Site
-
-
Brussels Capital
-
Jette, Brussels Capital, Belgien, 1090
- GSK Investigational Site
-
Woluwé-Saint-Lambert, Brussels Capital, Belgien, 1200
- GSK Investigational Site
-
-
Oost-Vlaanderen
-
Ghent, Oost-Vlaanderen, Belgien, 9000
- GSK Investigational Site
-
-
-
-
-
Joinville, Brasilien, 89201-260
- GSK Investigational Site
-
Natal, Brasilien, 59075-740
- GSK Investigational Site
-
Rio de Janeiro, Brasilien, 22775001
- GSK Investigational Site
-
São Paulo, Brasilien, 04537-080
- GSK Investigational Site
-
São Paulo, Brasilien, 05403-000
- GSK Investigational Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
- GSK Investigational Site
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasilien, 88020-210
- GSK Investigational Site
-
-
-
-
-
Beijing, China, 100191
- GSK Investigational Site
-
Beijing, China, 100020
- GSK Investigational Site
-
Changchun, China, 130012
- GSK Investigational Site
-
Guangzhou, China, 510060
- GSK Investigational Site
-
Guangzhou, China, 510515
- GSK Investigational Site
-
Hangzhou, China, 310003
- GSK Investigational Site
-
Jinan, China, 250012
- GSK Investigational Site
-
Nanjing, China, 210008
- GSK Investigational Site
-
Shenyang, China, 110001
- GSK Investigational Site
-
Suzhou, China, 215006
- GSK Investigational Site
-
Tianjin, China, 300020
- GSK Investigational Site
-
Zhengzhou, China, 450052
- GSK Investigational Site
-
-
-
-
-
Cologne, Deutschland, 50937
- GSK Investigational Site
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Deutschland, 89081
- GSK Investigational Site
-
-
Bavaria
-
München, Bavaria, Deutschland, 81377
- GSK Investigational Site
-
Würzburg, Bavaria, Deutschland, 97080
- GSK Investigational Site
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Deutschland, 40225
- GSK Investigational Site
-
-
Thuringia
-
Jena, Thuringia, Deutschland, 07747
- GSK Investigational Site
-
-
-
-
-
Amiens, Frankreich, 80054
- GSK Investigational Site
-
Caen, Frankreich, 14033
- GSK Investigational Site
-
Nice, Frankreich, 06200
- GSK Investigational Site
-
Paris, Frankreich, 75651
- GSK Investigational Site
-
Rennes, Frankreich, 35033
- GSK Investigational Site
-
-
-
-
-
Athens, Griechenland, 11528
- GSK Investigational Site
-
Thessaloniki, Griechenland, 54007
- GSK Investigational Site
-
-
East Macedonia and Thrace
-
Alexandroupoli, East Macedonia and Thrace, Griechenland, 681 00
- GSK Investigational Site
-
-
-
-
-
Jerusalem, Israel, 91120
- GSK Investigational Site
-
Kfar Saba, Israel, 44281
- GSK Investigational Site
-
Ramat Gan, Israel, 52621
- GSK Investigational Site
-
Tel Aviv, Israel, 64239
- GSK Investigational Site
-
-
-
-
-
Bergamo, Italien, 24127
- GSK Investigational Site
-
Bologna, Italien, 40138
- GSK Investigational Site
-
Brescia, Italien, 25123
- GSK Investigational Site
-
Catania, Italien, 95123
- GSK Investigational Site
-
Meldola FC, Italien, 47014
- GSK Investigational Site
-
Milan, Italien, 20133
- GSK Investigational Site
-
Ravenna, Italien, 48121
- GSK Investigational Site
-
Roma, Italien, 00168
- GSK Investigational Site
-
Siena, Italien, 53100
- GSK Investigational Site
-
Torino, Italien, 10126
- GSK Investigational Site
-
-
-
-
-
Aichi, Japan, 467-8602
- GSK Investigational Site
-
Aichi, Japan, 441-8570
- GSK Investigational Site
-
Aomori, Japan, 030-8553
- GSK Investigational Site
-
Ehime, Japan, 790-8524
- GSK Investigational Site
-
Fukuoka, Japan, 806-8501
- GSK Investigational Site
-
Fukuoka, Japan, 807-8555
- GSK Investigational Site
-
Fukuoka, Japan, 810-8563
- GSK Investigational Site
-
Fukuoka, Japan, 815-8555
- GSK Investigational Site
-
Gifu, Japan, 503-8502
- GSK Investigational Site
-
Gunma, Japan, 377-0280
- GSK Investigational Site
-
Hyōgo, Japan, 670-8540
- GSK Investigational Site
-
Kanagawa, Japan, 247-8533
- GSK Investigational Site
-
Kanagawa, Japan, 221-0855
- GSK Investigational Site
-
Kochi, Japan, 781-8555
- GSK Investigational Site
-
Nagano, Japan, 392-8510
- GSK Investigational Site
-
Okayama, Japan, 701-1192
- GSK Investigational Site
-
Osaka, Japan, 545-8586
- GSK Investigational Site
-
Osaka, Japan, 530-0012
- GSK Investigational Site
-
Shizuoka, Japan, 411-8777
- GSK Investigational Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada, T6G 1Z2
- GSK Investigational Site
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9
- GSK Investigational Site
-
Toronto, Ontario, Kanada, M4N 3M5
- GSK Investigational Site
-
-
Quebec
-
Montreal, Quebec, Kanada, H4J 1C5
- GSK Investigational Site
-
-
-
-
-
Christchurch, Neuseeland, 8011
- GSK Investigational Site
-
Dunedin, Neuseeland, 9054
- GSK Investigational Site
-
Takapuna Auckland, Neuseeland, 1309
- GSK Investigational Site
-
Wellington, Neuseeland, 6021
- GSK Investigational Site
-
-
-
-
-
Groningen, Niederlande, 9713 GZ
- GSK Investigational Site
-
-
South Holland
-
Dordrecht, South Holland, Niederlande, 3318 AT
- GSK Investigational Site
-
-
-
-
-
Chorzów, Polen, 41-500
- GSK Investigational Site
-
Krakow, Polen, 30510
- GSK Investigational Site
-
Lodz, Polen, 93-513
- GSK Investigational Site
-
Lublin, Polen, 20-081
- GSK Investigational Site
-
Lublin, Polen, 20-090
- GSK Investigational Site
-
Nowy Sącz, Polen, 33-300
- GSK Investigational Site
-
Poznan, Polen, 60-569
- GSK Investigational Site
-
Warsaw, Polen, 02-781
- GSK Investigational Site
-
-
-
-
-
Moscow, Russland, 125284
- GSK Investigational Site
-
Nizhny Novgorod, Russland, 603126
- GSK Investigational Site
-
Novosibirsk, Russland, 630087
- GSK Investigational Site
-
Saint Petersburg, Russland, 191024
- GSK Investigational Site
-
Saint Petersburg, Russland, 197 089
- GSK Investigational Site
-
Samara, Russland, 443021
- GSK Investigational Site
-
Saratov, Russland, 410028
- GSK Investigational Site
-
Ufa, Russland, 450083
- GSK Investigational Site
-
-
-
-
-
Barcelona, Spanien, 08035
- GSK Investigational Site
-
Barcelona, Spanien, 08916
- GSK Investigational Site
-
Cáceres, Spanien, 10003
- GSK Investigational Site
-
Gijón, Spanien, 33394
- GSK Investigational Site
-
L'Hospitalet de Llobrega, Spanien, 08908
- GSK Investigational Site
-
MOstoles Madrid, Spanien, 28933
- GSK Investigational Site
-
Madrid, Spanien, 28007
- GSK Investigational Site
-
Madrid, Spanien, 31008
- GSK Investigational Site
-
Murcia, Spanien, 30008
- GSK Investigational Site
-
PamplonaNavarra, Spanien, 31008
- GSK Investigational Site
-
Pozuelo de AlarcOn Madr, Spanien, 28223
- GSK Investigational Site
-
Salamanca, Spanien, 37007
- GSK Investigational Site
-
-
-
-
-
Pusan, Südkorea, 49241
- GSK Investigational Site
-
Seongnam-si Gyeonggi-do, Südkorea, 13620
- GSK Investigational Site
-
Seoul, Südkorea, 06351
- GSK Investigational Site
-
Seoul, Südkorea, 06591
- GSK Investigational Site
-
Ulsan, Südkorea, 44033
- GSK Investigational Site
-
-
-
-
-
Brno, Tschechien, 625 00
- GSK Investigational Site
-
Hradec Králové, Tschechien, 500 05
- GSK Investigational Site
-
Ostrava, Tschechien, 708 52
- GSK Investigational Site
-
Prague, Tschechien, 128 08
- GSK Investigational Site
-
-
-
-
Arizona
-
Yuma, Arizona, Vereinigte Staaten, 85364
- GSK Investigational Site
-
-
Kansas
-
Mission, Kansas, Vereinigte Staaten, 66205-2005
- GSK Investigational Site
-
-
North Carolina
-
Denver, North Carolina, Vereinigte Staaten, 80128
- GSK Investigational Site
-
-
Ohio
-
Blue Ash, Ohio, Vereinigte Staaten, 45242-5665
- GSK Investigational Site
-
-
Texas
-
Tyler, Texas, Vereinigte Staaten, 75702
- GSK Investigational Site
-
-
Virginia
-
Roanoke, Virginia, Vereinigte Staaten, 24014
- GSK Investigational Site
-
-
-
-
-
Bournemouth, Vereinigtes Königreich, BH7 7DW
- GSK Investigational Site
-
Cardiff, Vereinigtes Königreich, CF14 4XW
- GSK Investigational Site
-
Dundee, Vereinigtes Königreich, DD1 9SY
- GSK Investigational Site
-
Leicester, Vereinigtes Königreich, LE1 5WW
- GSK Investigational Site
-
London, Vereinigtes Königreich, W12 0NN
- GSK Investigational Site
-
Stoke-on-Trent, Vereinigtes Königreich, ST4 6QG
- GSK Investigational Site
-
Sutton, Vereinigtes Königreich, SM2 5PT
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Confirmed diagnosis of multiple myeloma as defined by the International Myeloma Working Group (IMWG) criteria.
-
Previously treated with at least 1 prior line of multiple myeloma (MM) therapy, and must have documented disease progression during or after their most recent therapy.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
-
Must have at least 1 aspect of measurable disease, defined as one of the following;
- Urine M-protein excretion >=200 mg per 24-hour, or
- Serum M-protein concentration >=0.5 grams per deciliter (g/dL), or
- Serum free light chain (FLC) assay: involved FLC level >=10 mg per dL (>=100 mg per liter) and an abnormal serum free light chain ratio (<0.26 or >1.65).
-
All prior treatment-related toxicities (defined by National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] version 5.0) must be <=Grade 1 at the time of enrollment, except for alopecia.
-
Adequate organ function
Exclusion Criteria:
- Intolerant to daratumumab.
- Refractory to daratumumab or any other anti-CD38 therapy (defined as progressive disease during treatment with anti-CD38 therapy, or within 60 days of completing that treatment).
- Intolerant to bortezomib, or refractory to bortezomib (defined as progressive disease during treatment with a bortezomib-containing regimen of 1.3 mg/m^2 twice weekly, or within 60 days of completing that treatment). Note: participants with progressive disease during treatment with a weekly bortezomib regimen are allowed.
- Ongoing Grade 2 or higher peripheral neuropathy or neuropathic pain.
- Prior treatment with anti-B-cell maturation antigen (anti-BCMA) therapy.
- Prior allogenic stem cell transplant.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions, including renal, liver, cardiovascular, or certain prior malignancies.
- Corneal epithelial disease.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Belantamab Mafodotin und Bortezomib plus Dexamethason (Arm A)
|
Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity |
|
Aktiver Komparator: Daratumumab und Bortezomib plus Dexamethason (Arm B)
|
Proteasome Inhibitor Synthetic glucocorticoid with anti-tumor activity Anti-cluster of differentiation 38 [CD-38] monoclonal antibody |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression-free Survival (PFS)
Zeitfenster: Up to approximately 41 months
|
PFS is defined as time from randomization until earliest date of disease progression (PD), determined by Independent Review Committee (IRC), according to the International Myeloma Working Group (IMWG) Response Criteria, or death due to any cause. PD= increase of >=25% from lowest value in >=1 of following (serum M-protein [absolute increase >=0.5 grams per deciliter {g/dL}]; serum M-protein increase >=1g/dL [when lowest M-protein >=5g/dL]; urine M-protein [absolute increase >=200 milligrams per 24 hours {mg/24h}]; participants without measurable serum & urine M-protein levels, difference between involved & uninvolved serum free light chains (sFLC) levels [absolute increase >10mg/dL]; appearance of new lesion,>=50% increase from nadir in Sum of the products of the maximal perpendicular diameters of measured lesions (SPD) of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter (cm) in short axis. |
Up to approximately 41 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Anzahl der Teilnehmer mit abnormalen Augenbefunden bei der augenärztlichen Untersuchung
Zeitfenster: Bis zu 73 Monate
|
Bis zu 73 Monate
|
|
|
Complete Response Rate (CRR)
Zeitfenster: Up to 73 months
|
CRR is defined as percentage of participants with a confirmed complete response or better. |
Up to 73 months
|
|
Overall Response Rate (ORR)
Zeitfenster: Up to 73 months
|
ORR is defined as percentage of participants with a confirmed partial response or better. |
Up to 73 months
|
|
Clinical Benefit Rate (CBR)
Zeitfenster: Up to 73 months
|
CBR is defined as percentage of participants with a confirmed minimal response (MR) or better |
Up to 73 months
|
|
Duration of Response (DoR)
Zeitfenster: Up to 73 months
|
DOR is defined as time from first documented evidence of partial response or better until first documented progression or death, whichever occurs first. |
Up to 73 months
|
|
Time to Response (TTR)
Zeitfenster: Up to 73 months
|
TTR is defined as time from the date of randomization and the first documented evidence of response (PR or better) among participants who achieve partial response or better. |
Up to 73 months
|
|
Time to Progression (TTP)
Zeitfenster: Up to 73 months
|
TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first. |
Up to 73 months
|
|
Overall Survival (OS)
Zeitfenster: Up to 73 months
|
OS is defined as time from the date of randomization until the date of death due to any cause. |
Up to 73 months
|
|
Progression-free Survival on Subsequent Line of Therapy (PFS2)
Zeitfenster: Up to 73 months
|
Progression-free survival on subsequent line of therapy is defined as time from randomization to disease progression after initiation of new anti-myeloma therapy or death from any cause, whichever occurs first. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier. |
Up to 73 months
|
|
Minimal Residual Disease (MRD) Negativity Rate
Zeitfenster: Up to 73 months
|
Minimal Residual Disease (MRD) negativity rate is defined as the percentage of participants who are MRD negative status by next generation sequencing (NGS). |
Up to 73 months
|
|
Number of Participants With Adverse Events (AEs)
Zeitfenster: Up to 73 months
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Hematology Parameters
Zeitfenster: Up to 73 months
|
Blood samples will be collected for the analysis of hematology parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Clinical Chemistry
Zeitfenster: Up to 73 months
|
Blood samples will be collected for the analysis of clinical chemistry parameters. |
Up to 73 months
|
|
Number of Participants With Clinically Significant Changes in Urine Dipstick
Zeitfenster: Up to 73 months
|
Urine samples will be collected for the urine dipstick analysis. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (Total Antibody) at Indicated Time Points
Zeitfenster: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Belantamab Mafodotin (ADC) at Indicated Time Points
Zeitfenster: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) at Indicated Time Points
Zeitfenster: Up to 73 months
|
Blood samples will be collected for PK analysis of belantamab mafodotin. |
Up to 73 months
|
|
Number of Participants With Positive Anti-drug Antibodies (ADAs) Against Belantamab Mafodotin
Zeitfenster: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be tested in screening assay, and positive samples will be further characterized for antibody titers. |
Up to 73 months
|
|
Titers of ADAs Against Belantamab Mafodotin
Zeitfenster: Up to 73 months
|
Serum samples collected for the analysis of the presence of ADAs using validated immunoassays. All samples will be to be further tested in screening assay, and positive samples will be further to be characterized for antibody titers. |
Up to 73 months
|
|
Number of Participants With Maximum Post-baseline Change From Baseline in Individual Items of Patient-Reported Outcome Version of the Common Term Criteria for Adverse Events (PRO-CTCAE)
Zeitfenster: Up to 73 months
|
The PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. |
Up to 73 months
|
|
Change From Baseline in Health Related Quality of Life (HRQoL) as Measured by EuropeanOrganization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30)
Zeitfenster: Up to 73 months
|
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning [PF], role functioning [RF], cognitive functioning [CF], emotional functioning [EF] and social functioning [SF]), three symptom scales (fatigue, pain and nausea/vomiting [N/V]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss [AL] and financial difficulties [FD]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology. Baseline was defined as latest pre-dose assessment (Day 1) with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. |
Up to 73 months
|
|
Change From Baseline in HRQoL as Measured by EORTC IL52
Zeitfenster: Up to 73 months
|
The EORTC Quality of Life Questionnaire 20-item Multiple Myeloma module (QLQMY20) is a supplement to the QLQ-C30 instrument used in participants with multiple myeloma. For the EORTC IL52, disease symptoms domain of the QLQ-MY20 will be used for bone aches or pain, back pain, hip pain, arm or shoulder pain, chest pain, and pain increasing with activity. The individual component scores in the disease symptom domain are averaged and transformed linearly to a score ranging from 0 to100. A high score for disease symptoms represents a high level of symptomatology or problems. A high score represents a high/healthy level of functioning. |
Up to 73 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: GSK Clinical Trials, GlaxoSmithKline
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Mateos MV, Trudel S, Quach H, Robak P, Beksac M, Pour L, Hus M, Kim K, Zherebtsova V, Delimpasi S, Jelinek T, Ward C, Ho PJ, Vorobyev V, Pitombeira de Lacerda M, Aparecida-Martinez G, Spicka I, Radocha J, Cavo M, Cerchione C, Fu C, Suzuki K, Rogers R, Phillips-Jones A, Wang Z, Baig H, Wilkes J, Zhou XL, Lewis E, Eccersley L, Sule N, Paka P, Opalinska JB, Mukhopadhyay P, Hungria V, Dimopoulos MA. Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials. Blood Adv. 2025 Nov 25;9(22):5708-5719. doi: 10.1182/bloodadvances.2025016949.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Martinez GA, Sureda Balari A, Sandhu I, Cerchione C, Ganly P, Dimopoulos MA, Fu C, Garg M, Abdallah AO, Gatt ME, Oriol Rocafiguera A, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Ficek J, Mantero A, Pirooz N, Varghese S, Lee J, McKeown A, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Mukhopadhyay P, Nielsen J, Opalinska J, Mateos MV; DREAMM-7 study investigators. Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial. Lancet Oncol. 2025 Aug;26(8):1067-1080. doi: 10.1016/S1470-2045(25)00330-4. Epub 2025 Jul 15.
- Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV; DREAMM-7 trial study group. Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial. Lancet Haematol. 2025 Aug;12(8):e599-e610. doi: 10.1016/S2352-3026(25)00163-2. Epub 2025 Jul 15.
- Hungria V, Robak P, Hus M, Zherebtsova V, Ward C, Ho PJ, Ribas de Almeida AC, Hajek R, Kim K, Grosicki S, Sia H, Bryant A, Pitombeira de Lacerda M, Aparecida Martinez G, Sureda Balari AM, Sandhu I, Cerchione C, Ganly P, Dimopoulos M, Fu C, Garg M, Abdallah AO, Oriol A, Gatt ME, Cavo M, Rifkin R, Fujisaki T, Mielnik M, Pirooz N, McKeown A, McNamara S, Zhou X, Nichols M, Lewis E, Rogers R, Baig H, Eccersley L, Roy-Ghanta S, Opalinska J, Mateos MV; DREAMM-7 Investigators. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Aug 1;391(5):393-407. doi: 10.1056/NEJMoa2405090. Epub 2024 Jun 1.
- Zhang X, Xing X, Wang Z, Wang K, Hua Y, Zhang L, Dong X. Threshold Price of Belantamab for Relapsed/Refractory Multiple Myeloma in China: A Cost-Effectiveness Analysis. Pharmacoecon Open. 2026 Sep 11. doi: 10.1007/s41669-026-00681-8. Online ahead of print.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Neubildungen
- Erkrankungen des Immunsystems
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Neubildungen, Plasmazelle
- Hämostasestörungen
- Paraproteinämien
- Bluteiweißstörungen
- Hämorrhagische Störungen
- Hämische und lymphatische Krankheiten
- Multiples Myelom
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Polycyclische Verbindungen
- Anorganische Chemikalien
- Schwangerschaft
- Schwangerschaft
- Steroide
- Fusions-Ring-Verbindungen
- Steroide, fluoriert
- Schwangerschaften
- Boronsäuren
- Säuren, nicht carboxylisch
- Säuren
- Borverbindungen
- Pyraziner
- Bortezomib
- Dexamethason
- Daratumumab
- Belantamab Mafodotin
Andere Studien-ID-Nummern
- 207503
- 2018 (US NIH Stipendium/Vertrag)
- 2018-003993-29 (Registrierungskennung: EudraCT (EU))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .